Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks

Shares of vaccine maker Novavax NVAX.O rise 13% to $7.06 premarket

Co says its COVID-19 vaccine is "approvable based on conversations with the U.S. Food and Drug Administration (FDA)"

NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval

The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month

Up to last close, stock had fallen 22.3% YTD